RxDoctor Payments Data

David Locklear, MD

Family Medicine · Maiden, NCNPI 1679535322

Payments from drug & device makers

$3,891in general payments, 2019–2025

Across 225 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$596
  • AbbVie$485
  • AstraZeneca$450
  • GSK$274
  • Pfizer$254
  • Lilly USA, LLC$249
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,891 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$130,901
Medicare patients
228
Services billed
1,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$100,716
MounjaroTirzepatide67$70,607
EliquisApixaban68$63,258
FarxigaDapagliflozin Propanediol39$44,768
RybelsusSemaglutide24$34,871
JardianceEmpagliflozin33$31,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$15,841
WegovySemaglutide11$15,553
JanumetSitagliptin Phos/Metformin Hcl11$14,134
TrintellixVortioxetine Hydrobromide15$11,247
Tresiba Flextouch U-200Insulin Degludec12$10,031
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$8,967
GemtesaVibegron19$8,964
JanuviaSitagliptin Phosphate13$6,663
Breo ElliptaFluticasone/Vilanterol17$6,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$596$151,140135 claims
Lilly USA, LLCMounjaro$249$70,60767 claims
PfizerEliquis$254$63,25868 claims
AstraZenecaFarxiga, Symbicort$450$48,15754 claims
Boehringer IngelheimJardiance$86$31,08033 claims
MerckJanumet, Januvia, Janumet Xr$38$26,86935 claims
GSKTrelegy Ellipta, Breo Ellipta$274$22,45843 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$11,24715 claims
Sumitomo Pharma America, Inc.Gemtesa$151$8,96419 claims
AbbVieSynthroid$485$4,67943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Maiden

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →